SPH-5030

N/A

Report date: 2024/04/26 20:00:28
NME

Base Information

Drug NameSPH-5030
Drug Alias NameSPH-5030
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsBile Duct Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSph (Benxi) North Pharmaceutical Co LtdShanghai Pharmaceuticals Holding Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsBile Duct Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A